2 penny stocks with a “strong buy” and a massive upward trend
Does High Risk Mean High Reward? Not necessarily, say the Wall Street pros. Citing penny stocks in particular or stocks that trade for less than $ 5 per share, analysts advise caution as these names may be in their infancy or face an uphill battle that is just too steep. These stocks, which attract investors with their bargain prices, could face strong headwinds or have poor fundamentals. However, analysts claim that there are early stage companies that reflect promising opportunities. The low stock prices mean you are getting significantly more bang for your buck. In addition, even a seemingly minor appreciation of the share price can lead to massive percentage gains. The final result? Not all risks are created equal. For this purpose, the professionals recommend carrying out due diligence before making an investment decision. Using TipRanks' database, we drew two penny stocks that received a consensus rating of “Strong Buy” from the analyst community. Not to mention that everyone has huge upside potential. Oncolytics Biotech (ONCY) We're starting Oncolytics, a biotechnology company focused on the use of immunotherapy combinations to treat cancer. The company's approach uses Pelareorep, an immuno-colytic virus, to deliver therapeutics that both target the tumor directly and activate the immune system's natural defenses. Oncolytics conducts its various research programs in collaboration with several big names in biotechnology, including Pfizer, Merck, Roche and Bristol-Myers Squibb. The company's development pipeline is testing the compatibility of Pelareorep with the cancer drugs of larger companies. So far, Pelareorep has shown positive results that have made early-stage breast cancer tumors more accessible for checkpoint inhibitor therapy. The data showed that pelareorep induced a robust anti-tumor immune response in some types of breast cancer. There are three ongoing clinical programs related to breast cancer: The company's Phase 2 AWARE 1 study, combining Pelareorep with Roche's anti-PD-L1 mAb Tecentriq, will assess the effects of the combination on breast cancer. Early response rate and studied overall survival. The phase 2 BRACELET-1 study is investigating the efficacy of Pelareorep in combination with Pfizer's anti-PD-L1 mAb Bavencio in breast cancer. A third phase 2 breast cancer study, IRENE, will evaluate Pelareorep's ability to improve outcomes in triple negative breast cancer. The study evaluates the safety and effectiveness of Pelareorep in combination with retifanlimab. The strong ONCY pipeline and the share price of $ 3.01 received high praise from the pros on Wall Street. HC Wainwright analyst Patrick Trucchio took an in-depth look at Oncolytics and concluded that the company offers a solid investment opportunity. “Oncolytics' lead compound, Pelareorep (Pela), we believe is about to demonstrate its potential to improve the treatment paradigms of multiple cancers. We believe it is the studies that could be done in Breast Cancer (BrCa), which is of significant value to shareholders in 2021 and beyond, ”said Trucchio. The analyst added, “Since the approval of the first OV T-VEC in 2015, at least eight licensing or acquisition agreements have been announced, including Merck's acquisition of Viralytics in February 2018 for $ 394 million and the acquisition of ViraTherapeutics im Valued at € 210 million from Boehringer Ingelheim in September 2018. Oncolytics has collaboration, supply and combination agreements with many major biopharmaceutical companies and organizations involved in cancer research. Positive data readings in any or all of the numerous combination studies with Pela and ICI could catalyze To that end, Trucchio rates ONCY a Buy, and its price target of $ 15 implies robust upside of ~ 397% for a year. (To see Trucchio's track record, click here.) Turning now to the rest of the road, other analysts are on the same page. With 5 buys and no holds or sells, the word on the street is that ONCY is a strong buy. Given the average target price of $ 8.51, investors could expect an uptrend of ~ 182%. (See ONCY stock analysis on TipRanks.) Xeris Pharmaceuticals (XERS) If we stick with the biotech sector, let's take a look at Xeris Pharmaceuticals. This company has one important advantage over many of its peers: it has a drug on the market that is approved for use. Gvoke, its self-administered glucagon injection device, was approved by the FDA in September 2019 for use in adults and children with severe blood sugar (hypoglycemia) due to diabetes. The product has generated revenue for Xeris for the past 5 quarters and that revenue began to grow in 2H20. In the company's most recent quarterly report for the fourth quarter of 20, Xeris saw Gvoke prescriptions rise 11% sequentially and quarterly revenue of $ 7.1 million. Total annual sales of the self-injection device were $ 20.2 million. In December 2020, the company also received a positive opinion from the European Medical Agency on Oglou, the space-stable liquid glucagon used in Gvoke, as well as approval from the European Commission for marketing from February 2021. Xeris is aiming to launch Oglou in Q4 21 The European Union. The company is not resting on its Gvoke laurels. It has an active development pipeline with several additional self-administered glucagon devices as well as additional drug candidates for the treatment of diabetes and epilepsy currently in development. Analyst Difei Yang, who writes from Mizuho, sees Gvoke as the key to Xeris' way forward. “Gvoke continued to gain market share during the quarter (we estimate the most recent weekly share at ~ 16%) from older glucagon kits. However, we note that the growth rate of the entire glucagon market has stagnated due to Covid-19. We forecast the glucagon market to accelerate again in 2H21 as Covid-19 wears off and expect Gvoke fundamentals to improve as the market growth rate accelerates, ”wrote Yang. Along with these comments, the analyst gave a buy rating on XERS shares and a price target of $ 14, which indicates growth of 225% for the coming year. (To see Yang's track record, click here.) This is another stock Wall Street likes, as shown by Strong Buy's unanimous consensus rating, derived from 3 recent positive ratings. Xeris shares are currently selling for $ 4.30, and their average price target of $ 10.67 implies an upside of ~ 148% in 2021. (See XERS stock analysis on TipRanks) To get good ideas for trading penny stocks too To find attractive reviews, visit the best stocks from TipRanks to Buy, a newly launched tool that brings together all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.